Online inquiry

IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7539MR)

This product GTTS-WQ7539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CLDN18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001002026.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51208
UniProt ID P56856
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7539MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4209MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ136MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ9787MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ1249MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ2645MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ4246MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ10355MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ5329MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW